Due to the very poor clinical outcome of some SHH medulloblastoma patients, the WHO has recently revised this classification, with new subclasses distinguishing between SHH, TP53 wild-type and SHH, TP53 mutant medulloblastoma7. The gene discussed is TP53; the disease is medulloblastoma.